SHAREHOLDER ALERT: Weiss Law Investigates Myovant Sciences Ltd.

NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Myovant Sciences Ltd. ("Myovant" or the "Company") (NYSE: MYOV) in connection with the proposed acquisition of the Company by Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. Under the terms of the merger agreement, the Company's shareholders will receive $27.00 in cash for each share of Myovant common stock owned. The transaction is valued at approximately $1.7 billion.